Conclusion: Probably overexpression of cyclin D1 implicates in the pathogenesis of the central giant cell granulomas but it seems that this protein could not be used as a marker for identifying the clinical behavior of these lesions.
Introduction
The term giant cell lesion (GCL) describes a group of intraosseous nonodontogenic benign lesions containing multinucleated giant cells (GCs). This category of the lesions comprises several entities in the jaws, including brown tumor of hyperparathyroidism, cherubism and the central giant cell granuloma (CGCG). [1] To date, controversies exist regarding the histogenesis of CGCGs of the jaws. Some researchers believe that this lesion represents a reactive lesion and because of the locally aggressive behavior of some lesions, the others accept it as a benign neoplasm. [2] [3] Most CGCGs of the jaws occur in females before age 30. Approximately 70% of cases arise in the mandi-ble. [2] Based on clinical and radiographic features, CGCGs can be categorized as aggressive or nonaggressive. [4] The aggressive type has three of five criteria defined as rapid growth, cortical bone thinning, or perforation, root resorption, and tooth displacement. Additionally, a CGCG greater than 5 cm or the lesions with greater recurrence potential after enucleation and curettage is classified as aggressive. The nonaggressive lesion, which comprises most cases of CGCGs, is often asymptomatic, grows slowly, and has a lower rate of recurrence. [4] Thus far, there are no reliable histologic or molecular methods to distinguish the two types from each other. [3] [4] Microscopically, these lesions are characterized by the presence of numerous multinucleated giant cells in a fibrocellular stroma of ovoid to spindle-shaped mononuclear cells (MCs). Foci of hemorrhage with hemosiderin pigment and newly formed osteoid or bone are occasionally observed. [5] Previous studies have demonstrated the expression of the cell cycle protein Ki-67 in the mononuclear cells of CGCGs, which shows the proliferative activity in these cells. [6] [7] This increases the possibility that deregulation of the cell cycle may play a role in pathogenesis of CGCGs.
The cell cycle comprises an ordered series of events that control defined cell cycle stage checkpoints and ultimate cell division. These events are regulated by the expression and degradation, activation and inactivation, and subcellular localization of cyclins and cyclindependent kinases (CDKs). [8] [9] [10] More than 15 cyclins have been identified, cyclins D, E, A, and B which appear sequentially during the cell cycle and bind to one or more CDK. [11] Genes encoding D-type cyclins (D1, D2, and D3) are induced by mitogenic stimuli. [12] In mammalian cells, CDK4 and CDK6 associate with Dtype cyclins and regulate G1 cell cycle phase progression. [8] [9] [10] [13] [14] Cyclin D1 is a member of cyclin protein family which is encoded by CCND1 (Cyclin D1 gene) gene on chromosome 11 and regulates the G1/S phase. CDK binds to cyclins and acquires catalytic activity. Activated CDKs in these complexes drive the cell cycle by phosphorylating proteins that are critical for cell cycle transitions. One such protein is the retinoblastoma susceptibility (RB) protein, which normally prevents cells from replicating by forming a tight, inactive complex with the transcription factor E2F. Phosphorylation of RB causes its release, which activates E2F and allows it to stimulate transcription of genes whose products drive cells through the cycle. [11] Because D-type cyclins provide the link between mitogenic signals and activation of the cell cycle [12, 15] and because of their regulatory function in the G1-to-S transition, [16] constitutive activation of the Dcyclin pathway can overcome or reduce specific mitogen requirements for cell proliferation [17] and thereby contribute to oncogenic transformation. [18] [19] [20] Therefore, the purpose of this study was to evaluate and compare the expression of cyclin D1 between aggressive and nonaggressive CGCGs of the jaws to define whether the neoplastic nature of the aggressive lesions.
Materials and Method

Case selection and demographic data of the cases
This retrospective study examined the records and tissue nonaggressive CGCG were studied.
Immunohistochemistry
Sections with 4µm thickness were cut from the paraffinembedded blocks and mounted on adherent glass slides.
Then deparaffinized in xylene and rehydrated in graded Immunostained sections were assessed and quantified by two investigators blinded to the clinical data for each case. Immunohistochemical reactivity of the multinucleated GCs and stromal mononuclear cells for cyclin D1 were scored on a scale from 1+ to 3+ in ten random selected fields at 400X magnification. Cases with 0-5% positive cells were scored 1+, 6-50% positive cells were scored 2+, and more than 50% were scored 3+. Immunopositivity in more than 5% of cells was considered indicative of overexpression. [21] [22] 
Statistical analysis
Student's t-test was used to compare the expression of cyclin D1 between two groups. Statistical analyses were performed using SPSS version 20 software. The p value of less than 0.05 was considered significant.
Results
Considering the inclusion and exclusion criteria mentioned above, thirty-two cases of central giant cell granuloma were retrieved consisting of 16 aggressive and 16
nonaggressive CGCGs. Table 1 Table   2 .
In the present study, overexpression of cyclin D1 was seen in all cases (32/32). Cyclin D1 positivity was seen predominantly in the nuclei of giant cells which had score 3+ in both groups. In aggressive CGCGs positivity of mononuclear cells of 50% of cases were in score 2+ and 50% in score 3+, while in nonaggressive CGCGs 68.8% were in score 2+ and 31.25% in score 3+. When a giant cell was positive, all the nuclei showed immunoreactivity. In both groups mean percentage of the positive GCs were higher than positive MCs (Table 3) . Signific- [21] [22] [23] [24] According to the results of different studies, [21] [22] [23] [24] it seems that cyclin D1 might play a role in the production of giant cells in these lesions.
In Kauzman et al. [22] study, cyclin D1 protein overexpression was present in 28 of 29 cases, and like our study, the GCs had higher expression. They also evaluated this protein on the granulomatous lesions and interestingly found that all the nuclei of GCs were negative for cyclin D1. Therefore, they suggested that the Kruse-Losler et al. [26] found no correlation with aggressiveness and expression of p53 and Ki-67.
In previous studies, [21] [22] one being a reactive process and other appears to be a true benign neoplasm, and that CCND1 amplification may contribute to the tumorigenesis of CGCLs. [28] In the present study, overexpression of cyclin D1
was seen in all cases in both GCs and MCs; however, the expression was higher in GCs than MCs, which is consistent with the results of other studies. 
